These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7857201)

  • 1. Effects of recombinant human interleukin 6 (rhIL-6) in marmosets (Callithrix jacchus). 1. General toxicity and hematological changes.
    Klug S; Neubert R; Stahlmann R; Thiel R; Ryffel B; Car BD; Neubert D
    Arch Toxicol; 1994; 68(10):619-31. PubMed ID: 7857201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (marmoset): comparison with studies in rats.
    Ryffel B; Weber M
    J Appl Toxicol; 1995; 15(1):19-26. PubMed ID: 7538156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.
    van Gameren MM; Willemse PH; Mulder NH; Limburg PC; Groen HJ; Vellenga E; de Vries EG
    Blood; 1994 Sep; 84(5):1434-41. PubMed ID: 8068939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate--the marmoset.
    Ryffel B; Car BD; Woerly G; Weber M; DiPadova F; Kammüller M; Klug S; Neubert R; Neubert D
    Blood; 1994 Apr; 83(8):2093-102. PubMed ID: 7512839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.
    Veldhuis GJ; Willemse PH; Sleijfer DT; van der Graaf WT; Groen HJ; Limburg PC; Mulder NH; de Vries EG
    J Clin Oncol; 1995 Oct; 13(10):2585-93. PubMed ID: 7595711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.
    Nieken J; Mulder NH; Buter J; Vellenga E; Limburg PC; Piers DA; de Vries EG
    Blood; 1995 Aug; 86(3):900-5. PubMed ID: 7542502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic effects of recombinant human interleukin-3 in vivo.
    Lindemann A; Ganser A; Herrmann F; Frisch J; Seipelt G; Schulz G; Hoelzer D; Mertelsmann R
    J Clin Oncol; 1991 Dec; 9(12):2120-7. PubMed ID: 1960553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
    Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
    Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys.
    Sun WH; Binkley N; Bidwell DW; Ershler WB
    Lymphokine Cytokine Res; 1993 Dec; 12(6):449-55. PubMed ID: 8123761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons.
    Herodin F; Mestries JC; Janodet D; Martin S; Mathieu J; Gascon MP; Pernin MO; Ythier A
    Blood; 1992 Aug; 80(3):688-95. PubMed ID: 1638022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects.
    Aoyama K; Uchida T; Takanuki F; Usui T; Watanabe T; Higuchi S; Toyoki T; Mizoguchi H
    Br J Clin Pharmacol; 1997 Jun; 43(6):571-8. PubMed ID: 9205816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey.
    Myers LA; Boyce JT; Robison RL
    Toxicology; 1995 Aug; 101(3):157-66. PubMed ID: 7545835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rhIL-11 on normal dogs and after sublethal radiation.
    Nash RA; Seidel K; Storb R; Slichter S; Schuening FG; Appelbaum FR; Becker AB; Bolles L; Deeg HJ; Graham T
    Exp Hematol; 1995 May; 23(5):389-96. PubMed ID: 7720811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the immunoglobulin-E system of the common marmoset in comparison with human data.
    Schmidt S; Neubert R; Schmitt M; Neubert D
    Life Sci; 1996; 59(9):719-30. PubMed ID: 8761025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
    Gordon MS; McCaskill-Stevens WJ; Battiato LA; Loewy J; Loesch D; Breeden E; Hoffman R; Beach KJ; Kuca B; Kaye J; Sledge GW
    Blood; 1996 May; 87(9):3615-24. PubMed ID: 8611685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo hematological effects of seven days of rhIL-6 in neonatal rats.
    Cairo MS; Plunkett JM; Clark S; van de Ven C
    Am J Pediatr Hematol Oncol; 1992; 14(1):44-7. PubMed ID: 1550262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
    Leonard JP; Neben TY; Kozitza MK; Quinto CM; Goldman SJ
    Exp Hematol; 1996 Feb; 24(2):270-6. PubMed ID: 8641352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates.
    Mayer P; Geissler K; Valent P; Ceska M; Bettelheim P; Liehl E
    Exp Hematol; 1991 Aug; 19(7):688-96. PubMed ID: 1909969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyhalogenated dibenzo-p-dioxins and dibenzofurans and the immune system. 4. Effects of multiple-dose treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on peripheral lymphocyte subpopulations of a non-human primate (Callithrix jacchus).
    Neubert R; Golor G; Stahlmann R; Helge H; Neubert D
    Arch Toxicol; 1992; 66(4):250-9. PubMed ID: 1514923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.